Member Info for Brand

Does anyone know if this page was already on the website before today?

It certainly looks like it's where results will be posted...

To the best of my understanding, sprinter passed a futility analysis aproxx halfway through the trial. We don't know what level of efficacy was required to continue recruitment, however if the company had the bar high, they could have a strong indication no?

Thank you for sharing GGGG

Marik

' If SNG have sight of top line data before this trial start, then this has positive implications, and if they don't have sight, it shows exceptional confidence in the product.'

So I think the options here are?

1. They had enough of a signal after the futility analysis

2. They were so bullish on success, they went for it blind

3. The trial completion date was actually weeks before the RNS for last patient recruited

Unless I've missed something?

'raised and discussed it'

Between your multiple accounts?

https://youtu.be/FG1NrQYXjLU

INFb smashes viruses

Bob

'The FDA needed to get out the news on Regeneron and Ely Lilli drugs being basically useless against Omicron before (and in this order) SNG release a great RNS and NIH confirm they are moving forward with SNG001 for both hospialised and out patients meeting the breathlessness criteria. This would be based on the cumulative data fro ACTIV-2 P2 & P3 plus Synairgen's P2 and P3 trials which combined demonstrate efficacy (for a class of paients) and, importantly, safety. GLA'

I think your speculation that there are many moving parts and many large entities involved in this roll out are probably correct. SNG is quite genuinely one of the most important companies on the planet atm. Should P3 replicate P2, it will be a seminal moment in this pandemic. It of course makes complete and total sense that there are huge moves going on in the background and that SNG will have to accommodate others when it comes to the timing and content of the big press release.

Whether today's news (in Vivo Omicron/catalant/Thermo fisher/combination w Paxlovid) are the final pieces of the puzzle... Well I guess we'll see tomorrow at 7am. But personally, and I expect most who frequent this would agree, whether it's tomorrow, next week or next month, SNG is about to drop an absolute science bomb on the world and we are the lucky/smart ones that knew about it first.

GLA

They certainly couldn't say it was for SNG001....

Thermo fisher have put out a release today as well...

https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/thermo-fisher-scientific-earns-nsf-133000906.html

US and UK sites :)

Today we've seen...

* Efficacy Vs Omicron
* Further efficacy when combined with Paxlovid
* Competition (mabs) out of the game
* Manufacturing scale up
* Evidence of decreased inf response in the obese
* Andybe/NDN so busy trying to deramp he's forgot which account he's on and posted w the wrong profile

A pretty damn good day and it's not even 4 o'clock :)

I recall something on this board about manufacturing upscale in Argentina. Anyone know the details of that one?

As much as this is of course really good news for SNG and investors. It's really damn good news for everyone.

I know covid of course 'isnt going away' but you add SNG to the other antiviral treatments and that really should be the end of covid restrictions for good.

Just drives the point that Covid really is just the start for SNG.

It's a really good point Saxondale, it's not just the west anymore.

A high proportion of American are overweight or obese full stop.

Nice one SNG2022. I Havent seen that one will check it out.

I am also really curious about the pathway via the lungs/respiratory system and if there is a the potential to work together with other treatments for non-respiratory viruses, IE could inhaled interferon beta replace the injections for MS with less side effects?

This para really got my attention:

"Further experiments showed that antiviral interferon-b effects were further increased in combination with nirmatrelvir (the antivirally active agent in paxlovid) and remdesivir"

It's not something I've seen really being discussed on here, but the fact that INFb stimulates the innate immune system should mean that it can combine with drugs that stimulate antibodies and/or antivirals that target the virus itself.

It would seem Dr Mary is on to this... And the potential beyond covid seems almost limitless. Would love to hear any genuine scientific thoughts on combining SNG001 with other treatments.

From Dr Mary's study, shared today by Welsh Falcon (thank you mate!)

https://www.biorxiv.org/content/10.1101/2022.01.20.477067v1

'Most notably, treatment with interferon-a, interferon-b, and interferon-g
revealed that the weaker interferon antagonism by Omicron virus isolates translates
into a profoundly increased Omicron sensitivity to interferon treatment (Figure 1E).

Further experiments showed that antiviral interferon-b effects were further increased
in combination with nirmatrelvir (the antivirally active agent in paxlovid) and remdesivir
(Figure 1F).

So far, clinical studies reported mixed outcomes in COVID-19 patients
treated with different interferons [18-21]. Given the newly discovered substantially
increased interferon sensitivity of Omicron viruses, interferons represent a promising
option for the treatment of Omicron patients.
In conclusion, we present further evidence that reduced interferon-antagonising
activity explains at least in part why Omicron variant infections are inherently less
severe than infections with other SARS-CoV-2 variants.

Most importantly, we here
also show that Omicron variant viruses display enhanced sensitivity to interferon
treatment, which makes interferons promising therapy candidates for Omicron
patients, in particular in combination with other antiviral agents.

What a hero Dr Mary is ...